Over 1m canadiens on medical cannabis
A recent study conducted by PricewaterhouseCoopers for Health Canada indicated that more than 1,000,000 Canadians currently rely upon medical cannabis for relief from pain, nausea and loss of appetite. Cannabis clubs formed across Canada in response to the incredible demand for a safe and reliable source of medical cannabis. These clubs obtain cannabis to members who provide a verifiable letter of diagnosis for a chronic or terminal illnesses from a physician. The senate recognizes cannabis clubs as a primary source of awareness of education.

Cannabis As Living Medicine (C.A.L.M.) is a national, peer-run organization that provides more than 1,700 Canadians living with severe or chronic illnesses with safe and continuous access to medicinal cannabis in a safe empowering environment. C.A.L.M. is Eastern Canadas first medical cannabis club, established in 1996, and serves members in the Greater Toronto Area and across Canada. Currently, C.A.L.M. is a superior dispenser of medical cannabis that functions like a wellness centre. C.A.L.M. is open seven days a week in order to provide clients with consistent and reliable access to medical cannabis.

Cannabis is once again becoming a medically recognized form of medicine around the world. Canadians overwhelmingly support the legalization of medical cannabis (90%). C.A.L.M. welcomes all inquiries regarding cannabis as medicine.

Currently, the biggest hurdle to the medical use of cannabis is its politicization and legality. These hurdles burden Canadas most vulnerable people with concerns of safety and expense, and expose them to the threat of criminal prosecution. At the same time these medical users have little to no regulation of the medicine they use. It is a long term goal of C.A.L.M. to help overcome the stigma and other obstacles that prevent the full benefits of cannabis from being realized.

morning all

GW Pharmaceuticals PLC
22 March 2007





GW and Otsuka Receive Hart-Scott-Rodino Clearance for Sativex(R) US License
Agreement

22 March 2007: GW Pharmaceuticals plc and Otsuka Pharmaceutical Co. Ltd today
announce that they have each received early termination by the United States
Federal Trade Commission and the Antitrust Division of the United States
Department of Justice of the required waiting period under the Hart-Scott-Rodino
Antitrust Improvements Act of 1976 with respect to the development and license
agreement announced on 14 February 2007 granting Otsuka exclusive rights to
develop and market Sativex(R), GW's lead product, in the United States. With
the grant of HSR clearance, GW and Otsuka have now received the approval of the
U.S. antitrust authorities necessary to close the transaction.

On 14 February 2007, GW and Otsuka announced that they had entered into a major
long term strategic cannabinoid alliance. The relationship has commenced with
the grant to Otsuka of an exclusive license to develop and market Sativex in the
U.S. The companies are also in detailed discussions with a view to entering
into a cannabinoid research collaboration in the field of Central Nervous System
(CNS) disorders and cancer treatment in order to research, develop and
commercialize a range of other early stage cannabinoid product opportunities.